Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors

Vascular. 2014 Aug;22(4):313-6. doi: 10.1177/1708538113502648. Epub 2013 Sep 2.

Abstract

Thromboangiitis obliterans, or Buerger's disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment. Although two randomized trials have demonstrated a role for intravenous iloprost, no oral drug has yet been demonstrated to be effective in treating thromboangiitis obliterans. We present the first three reported cases of thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors, followed by a discussion of the rationale for the use of these agents in thromboangiitis obliterans.

Keywords: Thromboangiitis obliterans; phosphodiesterase inhibitors; therapeutics.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Hand / blood supply*
  • Humans
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Thromboangiitis Obliterans / diagnosis
  • Thromboangiitis Obliterans / drug therapy*
  • Thromboangiitis Obliterans / enzymology
  • Treatment Outcome

Substances

  • Phosphodiesterase 5 Inhibitors